This not only identifies ASS1 as a core target of EVO in regulating arginine metabolism but also demonstrates that the combination of EVO and targeted ASS1 inhibition can enhance anti-tumor effects by synergistically reducing arginine synthesis. The gene discussed is ASS1; the disease is neoplasm.